Glass House Brands (GLAS) Cash & Equivalents (2020 - 2026)
Glass House Brands' (GLAS) quarterly Cash & Equivalents came in at $27.9 million in Q1 2026, down 25.76% year-on-year from $37.6 million in Q1 2025, and up 40.69% on a QoQ basis from $19.8 million in Q4 2025.
Glass House Brands (GLAS) Cash & Equivalents (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Cash & Equivalents data on file, last reported at $27.9 million in Q1 2026.
- On a quarterly basis, Cash & Equivalents fell 25.76% year-over-year to $27.9 million in Q1 2026; TTM through Mar 2026 was $27.9 million, a 25.76% decrease from a year earlier, with the FY2025 full-year figure at $19.8 million, down 41.49% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $27.9 million, up from $19.8 million in the prior quarter.
- Over the last five years, Cash & Equivalents for GLAS reached as high as $44.2 million in Q2 2025 and fell as low as $11.1 million in Q4 2022.
- Historically, Cash & Equivalents has averaged $26.8 million across 5 years, with a median of $25.9 million in 2024.
- Across the five-year window, Cash & Equivalents plunged 93.34% in 2022 and surged 164.94% in 2023, its largest moves.
- Year by year, Cash & Equivalents stood at $11.1 million in 2022, then jumped by 164.94% to $29.5 million in 2023, then increased by 14.9% to $33.9 million in 2024, then slumped by 41.49% to $19.8 million in 2025, then soared by 40.69% to $27.9 million in 2026.
- Per Business Quant data, the three most recent Cash & Equivalents figures were $27.9 million in Q1 2026, $19.8 million in Q4 2025, and $29.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 1.76 Bn |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 3.79 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 1.28 Bn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | 3.97 Mn |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 266.50 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | 27.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.93 Mn |
| Dec 31, 2025 | 19.85 Mn |
| Sep 30, 2025 | 29.77 Mn |
| Jun 30, 2025 | 44.20 Mn |
| Mar 31, 2025 | 37.62 Mn |
| Dec 31, 2024 | 33.92 Mn |
| Sep 30, 2024 | 35.06 Mn |
| Jun 30, 2024 | 25.88 Mn |
| Mar 31, 2024 | 24.41 Mn |
| Dec 31, 2023 | 29.52 Mn |
| Sep 30, 2023 | 37.89 Mn |
| Jun 30, 2023 | 22.69 Mn |
| Mar 31, 2023 | 16.37 Mn |
| Dec 31, 2022 | 11.14 Mn |
| Sep 30, 2022 | 17.54 Mn |
| Jun 30, 2022 | 17.45 Mn |
| Mar 31, 2022 | 24.83 Mn |
| Dec 31, 2021 | 51.07 Mn |
| Sep 30, 2021 | 28.86 Mn |
| Jun 30, 2021 | 134.28 Mn |